Emanuel Severus

Emanuel Severus

Auto-generated profile, based on publicly available information

Emanuel Severus

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2014 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
ESEmanuel Severus
Emanuel Severus
MTMatthew J Taylor
Matthew J Taylor
CSCathrin Sauer
Cathrin Sauer
APAndrea Pfennig
Andrea Pfennig
PRPhilipp Ritter
Philipp Ritter
JGJohn R Geddes
John R Geddes
In a previous meta-analysis of randomized controlled trials comparing lithium with placebo as a long-term treatment in bipolar disorders, we observed a clear preventative effect for manic episodes; however, the effect was equivocal for depressive episodes. Since then, the evidence base has grown further. In this update, we furthermore present the data on efficacy of lithium in comparison to alternative drug treatments. In addition, we analyze the data comparing lithium with placebo and other treatments regarding drop-outs due to reasons other than a mood episode and completion of study (no mood episode and no drop-out to reasons other than a mood episode). Randomized controlled trials (RCTs) were sought comparing lithium with placebo and lithium with an alternative treatment in bipolar disorders where the stated intent of treatment was prevention of mood episodes. To this purpose, the Cochrane Central Register of Controlled Trials (CENTRAL) was searched. Reference lists of relevant papers and major textbooks of mood disorders were examined. Authors, other experts in the field, and pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished. For the comparison of lithium with placebo, seven trials (1,580 participants) were included. Lithium was more effective than placebo in preventing overall mood episodes (random effects RR 0.66, 95% CI 0.53 to 0.82), manic episodes (random effects RR 0.52, 95% CI 0.38 to 0.71), and, dependent on the type of analyses applied, depressive episodes (random effects RR 0.78, 95% CI 0.59 to 1.03; fixed effect RR 0.73, 95% CI 0.60 to 0.88). Lithium was inferior to placebo in leading to drop-outs for reasons other than a mood episode (random effects RR 1.33, 95% CI 1.07 to 1.65) but superior to placebo on study completion (random effects RR 1.69, 95% CI 1.12 to 2.55). For the comparison of lithium with anticonvulsants, seven trials were included (n = 1,305). In prevention of manic episodes, lithium showed superiority compared to anticonvulsants (random effects RR 0.66, 95% CI 0.44 to 1.00). However, there was no significant difference regarding prevention of overall mood episodes, depressive episodes, dropping-out to reasons other than a mood episode, or study completion. The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable treatment option in this indication.

24 May 2012 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
Konstantinos N FountoulakisKonstantinos N Fountoulakis
Konstantinos N Fountoulakis
SKSiegfried Kasper
Siegfried Kasper
OAOle Andreassen
Ole Andreassen
PBPierre Blier
Pierre Blier
AOAhmed Okasha
Ahmed Okasha
Eduard VietaEduard Vieta
Eduard Vieta

8 December 2020 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
SDSeetal Dodd
Seetal Dodd
MBMichael Bauer
Michael Bauer
Andre CarvalhoAndre Carvalho
Andre Carvalho
HEHarris Eyre
Harris Eyre
MFMaurizio Fava
Maurizio Fava
MBMichael Berk
Michael Berk
Major depressive disorder is a common, recurrent, disabling and costly disorder that is often severe and/or chronic, and for which non-remission on guideline concordant first-line antidepressant tr...

23 August 2013 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
ESEmanuel Severus
Emanuel Severus
MBMichael Bauer
Michael Bauer

21 November 2016 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
PRPhilipp S. Ritter
Philipp S. Ritter
FBFelix Bermpohl
Felix Bermpohl
OGOliver Gruber
Oliver Gruber
MHMartin Hautzinger
Martin Hautzinger
AJAndreas Jansen
Andreas Jansen
MBMichael Bauer
Michael Bauer
Bipolar disorder is a severe and heterogeneous mental disorder. Despite great advances in neuroscience over the past decades, the precise causative mechanisms at the transmitter, cellular or network level have so far not been unraveled. As a result, individual treatment decisions cannot be tailor-made and the uncertain prognosis is based on clinical characteristics alone. Although a subpopulation of patients have an excellent response to pharmacological monotherapy, other subpopulations have been less well served by the medical system and therefore require more focused attention. In particular individuals at high risk of bipolar disorder, young patients in the early stages of bipolar disorder, patients with an unstable highly relapsing course and patients with acute suicidal ideation have been identified as those in need. A research consortium of ten universities across Germany has therefore implemented a 4 year research agenda including three randomized controlled trials, one epidemiological trial and one cross-sectional trial to address these areas of unmet needs. The topics under investigation will be the improvement of early recognition, specific psychotherapy, and smartphones as an aid for early episode detection and biomarkers of lithium response. A subset of patients will be investigated utilizing neuroimaging (fMRI), neurophysiology (EEG), and biomaterials (genomics, transcriptomics). This article aims to outline the rationale, design, and methods of these individual studies.

13 June 2018 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
ESEmanuel Severus
Emanuel Severus
MBMichael Bauer
Michael Bauer
JGJohn Geddes
John Geddes
For more than 40 years, lithium has been the gold standard in the long-term treatment of bipolar disorders. In the course of the last 15 years, other drugs have been approved in this indication and are widely used in clinical practice at the expense of lithium. New research from the last few years, however, indicates that lithium is still the first-line treatment in this indication. Against this background and lithium’s proven acute antimanic efficacy, we should perhaps be using lithium more regularly (in combination with an atypical antipsychotic, if necessary) right from the start for the acute treatment of a manic episode and, once remission has been achieved and euthymia maintained during continuation treatment, to regularly taper off the atypical antipsychotic, if possible, and continue with lithium as monotherapy for prophylactic treatment. This might lead to lithium being used more consistently with the scientific evidence in the long-term treatment of bipolar disorders. It remains uncertain, however, to predict who will respond to and tolerate lithium prophylactically, and more research is needed to deliver the best possible individualized care to our patients.